Athenex, Inc. (ATNX): Price and Financial Metrics


Athenex, Inc. (ATNX)

Today's Latest Price: $13.70 USD

0.15 (-1.08%)

Updated Jan 28 9:04am

Add ATNX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 241 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ATNX Stock Summary

  • Athenex Inc's stock had its IPO on June 14, 2017, making it an older stock than just 12.14% of US equities in our set.
  • With a year-over-year growth in debt of 107.33%, Athenex Inc's debt growth rate surpasses 88.96% of about US stocks.
  • Revenue growth over the past 12 months for Athenex Inc comes in at 78.06%, a number that bests 93.39% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Athenex Inc, a group of peers worth examining would be BBI, QUIK, TMDX, RIGL, and ACLS.
  • Visit ATNX's SEC page to see the company's official filings. To visit the company's web site, go to www.athenex.com.

ATNX Stock Price Chart Interactive Chart >

Price chart for ATNX

ATNX Price/Volume Stats

Current price $13.70 52-week high $15.67
Prev. close $13.85 52-week low $5.63
Day low $13.70 Volume 7,111
Day high $13.70 Avg. volume 831,845
50-day MA $12.32 Dividend yield N/A
200-day MA $11.82 Market Cap 1.28B

Athenex, Inc. (ATNX) Company Bio


Athenex Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The company was founded in 2003 and is based in Buffalo, New York.


ATNX Latest News Stream


Event/Time News Detail
Loading, please wait...

ATNX Latest Social Stream


Loading social stream, please wait...

View Full ATNX Social Stream

Latest ATNX News From Around the Web

Below are the latest news stories about Athenex Inc that investors may wish to consider to help them evaluate ATNX as an investment opportunity.

CEO Dr. Johnson Lau Recuperating from COVID at Home

BUFFALO, N.Y., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its CEO and Board Chairman, Dr. Johnson Lau, has been discharged from the hospital and is doing well recuperating at home. He continues to carry out the full duties and responsibilities of CEO and Chairman of Athenex. About Athenex, Inc.Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology I...

Yahoo | January 25, 2021

When Can We Expect A Profit From Athenex, Inc. (NASDAQ:ATNX)?

We feel now is a pretty good time to analyse Athenex, Inc.'s ( NASDAQ:ATNX ) business as it appears the company may be...

Yahoo | January 10, 2021

CEO Dr. Johnson Lau Contracts COVID-19

BUFFALO, N.Y., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that its CEO and Board Chairman, Dr. Johnson Lau, has contracted COVID-19. Dr. Lau is receiving oral and intravenous treatment at a local hospital, and his condition is currently stable. Dr. Lau is communicating with senior management and continues to serve as Athenex’s CEO. Under the advice of his physician, he will not be able to attend the 39th Annual J.P. Morgan Healthcare Conference. Athenex’s senior management team will continue to participate and present at the 39th Annual J.P. Morgan Healthcare Conference at its previously s...

Yahoo | January 8, 2021

Athenex to Present at the 39th Annual J.P. Morgan Healthcare Conference

BUFFALO, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that it will participate in the 39th annual J. P. Morgan Healthcare Conference. Johnson Lau, CEO and Board Chairman, and Daniel Lang, Senior Director, Corporate Development, will present a corporate overview at the conference. When: Monday, January 11, 2021, at 8:40 AM ETWhere: Conference Virtual SessionA live audio webcast of the presentation and replay will be available in the “Events & Presentations” section of the Athenex website at https://ir.athenex.com/investor-calendar.About Athenex, Inc. Founded in 2003, Athenex, Inc. is ...

Yahoo | January 5, 2021

Athenex (ATNX) Gets FDA Approval for Skin Treatment Klisyri

Athenex (ATNX) wins the FDA nod for Klisyri as a topical treatment of actinic keratosis on the face or scalp. The drug will be launched in the first quarter of 2021 in the United States.

Yahoo | December 16, 2020

Read More 'ATNX' Stories Here

ATNX Price Returns

1-mo 23.20%
3-mo 20.18%
6-mo 29.12%
1-year -4.06%
3-year -8.79%
5-year N/A
YTD 23.87%
2020 -27.57%
2019 20.33%
2018 -20.19%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.862 seconds.